These include Cancer Antigen 125 (CA125) for ovarian cancer (17, 35), cancer antigen 19-9 (CA 19-9) for pancreatic cancer (36), cancer antigen 15-3 (CA 15-3) for breast cancer (37), prostate-specific antigen (PSA) for prostate cancer (15), and carcinoembryonic antigen (CEA) increases in colorectal, bladder, breast, pancreatic and lung cancer (38). This evidence concerns the gene CEACAM5 and ovarian cancer.